CO5261517A1 - Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis - Google Patents
Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosisInfo
- Publication number
- CO5261517A1 CO5261517A1 CO00087459A CO00087459A CO5261517A1 CO 5261517 A1 CO5261517 A1 CO 5261517A1 CO 00087459 A CO00087459 A CO 00087459A CO 00087459 A CO00087459 A CO 00087459A CO 5261517 A1 CO5261517 A1 CO 5261517A1
- Authority
- CO
- Colombia
- Prior art keywords
- buprenorfine
- buprenorphine
- nalmefen
- naltrexone
- naloxone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
una composición analgésica bajo la forma de una unidad de dosificación parenteral o bajo la forma de una unidad de dosificación adecuada para una administración vía la mucosa que comprende una cantidad de buprenorfina que es menor a la dosis clínica requerida para lograr el alivio del dolor y una cantidad de naloxona tal que la relación de peso entre la buprenorfina y la naloxona esta en el rango de entre 12.5 a 1 y 27.5 a 1, o una cantidad de naltrexona o de nalmefen tal que la relación de peso entre la buprenorfina y la naltrexona o el nalmefen esta en el rango de entre 12.5 a 1 y 22.5 a 1, donde la acción analgésica de la buprenorfina se ve potenciada por la baja dosis de naloxona, de naltrexona o de nalmefen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9927359.1A GB9927359D0 (en) | 1999-11-19 | 1999-11-19 | Improvements in or relating to organic compositions |
US17620800P | 2000-01-14 | 2000-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261517A1 true CO5261517A1 (es) | 2003-03-31 |
Family
ID=26316086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00087459A CO5261517A1 (es) | 1999-11-19 | 2000-11-17 | Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis |
Country Status (31)
Country | Link |
---|---|
US (4) | US6995169B2 (es) |
EP (1) | EP1242087B1 (es) |
JP (1) | JP4745576B2 (es) |
KR (1) | KR100726699B1 (es) |
CN (1) | CN100431543C (es) |
AR (1) | AR031682A1 (es) |
AT (1) | ATE262335T1 (es) |
AU (1) | AU777259B2 (es) |
BR (1) | BR0015580A (es) |
CA (1) | CA2392013C (es) |
CO (1) | CO5261517A1 (es) |
CZ (1) | CZ303160B6 (es) |
DE (1) | DE60009346T2 (es) |
DK (1) | DK1242087T3 (es) |
ES (1) | ES2214334T3 (es) |
GB (1) | GB2356348B (es) |
HK (1) | HK1055389A1 (es) |
HU (1) | HU229565B1 (es) |
IL (2) | IL149580A0 (es) |
MX (1) | MXPA02004978A (es) |
NO (1) | NO321965B1 (es) |
NZ (1) | NZ519023A (es) |
PL (1) | PL199727B1 (es) |
PT (1) | PT1242087E (es) |
RO (1) | RO121174B1 (es) |
RU (1) | RU2255737C2 (es) |
SI (1) | SI21025B (es) |
SK (1) | SK286888B6 (es) |
TR (1) | TR200400653T4 (es) |
TW (1) | TW550070B (es) |
WO (1) | WO2001035942A2 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
US7375111B2 (en) | 2003-04-29 | 2008-05-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
LT1765292T (lt) | 2004-06-12 | 2018-01-10 | Collegium Pharmaceutical, Inc. | Nuo piktnaudžiavimo apsaugotos vaistų formos |
DK2135603T3 (da) * | 2005-11-22 | 2013-03-25 | Orexigen Therapeutics Inc | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
CA2674915C (en) * | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
EP2089010A1 (en) | 2006-10-24 | 2009-08-19 | The John Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
KR20150082689A (ko) | 2006-11-09 | 2015-07-15 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
US20080199407A1 (en) | 2007-02-15 | 2008-08-21 | Slater Kenneth C | Drug Detoxification Protocol Using Microdosing |
GB2447014A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
GB2447015A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
JP2010537989A (ja) * | 2007-09-03 | 2010-12-09 | ナノセラピューティクス・インコーポレイテッド | 難溶性薬物の組成物及び送達方法 |
US20090082383A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched buprenorphine |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
EP3659604A1 (en) | 2010-01-11 | 2020-06-03 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
SG10201510564PA (en) | 2010-12-22 | 2016-01-28 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
RS62505B1 (sr) | 2011-09-19 | 2021-11-30 | Orexo Ab | Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson |
BR112014030282A2 (pt) | 2012-06-06 | 2017-06-27 | Orexigen Therapeutics Inc | métodos de tratamento de excesso de peso e obesidade |
US20150342946A1 (en) | 2013-01-30 | 2015-12-03 | Pharmorx Therapeutics, Inc. | Treatments For Depression And Other Diseases With A Low Dose Agent |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
JP2016529328A (ja) * | 2013-09-10 | 2016-09-23 | インシス・ファーマ・インコーポレーテッド | 舌下ブプレノルフィンスプレー |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
JP6797691B2 (ja) | 2014-04-22 | 2020-12-09 | 大塚製薬株式会社 | ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途 |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
CA3166250A1 (en) * | 2020-02-05 | 2021-08-12 | Gregory G. Plucinski | Drug products for intranasal administration and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB8430109D0 (en) | 1984-11-29 | 1985-01-09 | Gkn Technology Ltd | Securing components |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB2213058B (en) * | 1987-12-03 | 1991-07-17 | Reckitt & Colmann Prod Ltd | Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
AU5956001A (en) * | 2000-05-05 | 2001-11-20 | Pain Therapeutics Inc | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
-
2000
- 2000-11-16 AR ARP000106062A patent/AR031682A1/es unknown
- 2000-11-17 SI SI200020061A patent/SI21025B/sl not_active IP Right Cessation
- 2000-11-17 GB GB0028088A patent/GB2356348B/en not_active Expired - Fee Related
- 2000-11-17 BR BR0015580-2A patent/BR0015580A/pt not_active Application Discontinuation
- 2000-11-17 NZ NZ519023A patent/NZ519023A/en not_active IP Right Cessation
- 2000-11-17 RU RU2002116361/15A patent/RU2255737C2/ru not_active IP Right Cessation
- 2000-11-17 EP EP00977658A patent/EP1242087B1/en not_active Expired - Lifetime
- 2000-11-17 WO PCT/GB2000/004372 patent/WO2001035942A2/en active IP Right Grant
- 2000-11-17 CZ CZ20022121A patent/CZ303160B6/cs not_active IP Right Cessation
- 2000-11-17 IL IL14958000A patent/IL149580A0/xx active IP Right Grant
- 2000-11-17 CA CA002392013A patent/CA2392013C/en not_active Expired - Fee Related
- 2000-11-17 AT AT00977658T patent/ATE262335T1/de active
- 2000-11-17 SK SK876-2002A patent/SK286888B6/sk not_active IP Right Cessation
- 2000-11-17 PL PL355330A patent/PL199727B1/pl unknown
- 2000-11-17 PT PT00977658T patent/PT1242087E/pt unknown
- 2000-11-17 DK DK00977658T patent/DK1242087T3/da active
- 2000-11-17 AU AU15297/01A patent/AU777259B2/en not_active Ceased
- 2000-11-17 KR KR1020027006375A patent/KR100726699B1/ko not_active IP Right Cessation
- 2000-11-17 MX MXPA02004978A patent/MXPA02004978A/es active IP Right Grant
- 2000-11-17 CN CNB008159181A patent/CN100431543C/zh not_active Expired - Fee Related
- 2000-11-17 TR TR2004/00653T patent/TR200400653T4/xx unknown
- 2000-11-17 HU HU0203588A patent/HU229565B1/hu not_active IP Right Cessation
- 2000-11-17 JP JP2001537935A patent/JP4745576B2/ja not_active Expired - Fee Related
- 2000-11-17 CO CO00087459A patent/CO5261517A1/es active IP Right Grant
- 2000-11-17 RO ROA200200620A patent/RO121174B1/ro unknown
- 2000-11-17 DE DE60009346T patent/DE60009346T2/de not_active Expired - Lifetime
- 2000-11-17 ES ES00977658T patent/ES2214334T3/es not_active Expired - Lifetime
-
2001
- 2001-01-29 TW TW090101624A patent/TW550070B/zh not_active IP Right Cessation
-
2002
- 2002-05-09 IL IL149580A patent/IL149580A/en not_active IP Right Cessation
- 2002-05-14 US US10/145,284 patent/US6995169B2/en not_active Expired - Fee Related
- 2002-05-15 NO NO20022330A patent/NO321965B1/no not_active IP Right Cessation
-
2003
- 2003-10-20 HK HK03107582.6A patent/HK1055389A1/xx not_active IP Right Cessation
-
2005
- 2005-10-20 US US11/254,602 patent/US7402591B2/en not_active Expired - Fee Related
- 2005-10-20 US US11/254,988 patent/US20060058333A1/en not_active Abandoned
- 2005-10-20 US US11/254,525 patent/US20060069113A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261517A1 (es) | Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis | |
AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
US5665378A (en) | Transdermal therapeutic formulation | |
AR065580A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
GT200100211AA (es) | Compuestros de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos. (patentefraccionaria no. 1 de la solicitud de patente de invencion no. pi-2001-0211. | |
PE20001396A1 (es) | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista | |
WO2001082914A3 (en) | Topical anesthetic/opioid formulations and uses thereof | |
ES2074513T3 (es) | Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo. | |
ES2091441T3 (es) | Composicion farmaceutica. | |
NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
AR012615A1 (es) | Tableta de liberacion controlada de drogas administradas por via sublingual o bucal | |
AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
NO20030897D0 (no) | Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer | |
EP1444984B1 (en) | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes | |
AR011133A1 (es) | MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA. | |
AR065581A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
ES2171440T3 (es) | Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal. | |
BR0114100A (pt) | Formulações de liberação controlada para administração oral | |
AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
AR030957A1 (es) | Composiciones de analgesico y glucosamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |